- ¥1390 - 4990
- Solarbio
- 北京
- IG3310
- 2026年08月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
AI 赋能培养基定制开发：CHO 培养基是如何实现产量提升Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
GDC-0834
- 库存：
999
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1133432-49-1
- 规格：
1mg/5mg/10mg
| 规格： | 1mg | 产品价格： | ¥1390.00 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ¥3490.00 |
| 规格： | 10mg | 产品价格： | ¥4990.00 |
| CAS | 1133432-49-1 |
| 英文名称 | GDC-0834 |
| 分子式 | C33H36N6O3S |
| 分子量 | 596.74 |
| 规格 | 1mg ; 5mg ; 10mg |
| 溶解性 | Soluble in DMSO ≥3mg/mL(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | Light yellow to yellow Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 | 冷藏运输 |
| MDL | MFCD22665722 |
| SMILES | CC1=C(C=CC=C1NC(=O)C2=CC3=C(S2)CCCC3)C4=CN(C(=O)C(=N4)NC5=CC=C(C=C5)[C@@H]6C(=O)N(CCN6C)C)C |
| InChIKey | CDOOFZZILLRUQH-GDLZYMKVSA-N |
| InChI | InChI=1S/C33H36N6O3S/c1-20-24(9-7-10-25(20)36-31(40)28-18-22-8-5-6-11-27(22)43-28)26-19-39(4)33(42)30(35-26)34-23-14-12-21(13-15-23)29-32(41)38(3)17-16-37(29)2/h7，9-10，12-15，18-19，29H，5-6，8，11，16-17H2，1-4H3，(H，34，35)(H，36，40)/t29-/m1/s1 |
| PubChem CID | 25234918 |
| 靶点 | Btk |
| 通路 | Protein Tyrosine Kinase/RTK;Angiogenesis |
| 背景说明 | GDC-0834 是一种有效的选择性 BTK 抑制剂。 |
| 生物活性 | GDC-0834 is a potent and selective BTK inhibitor. GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays， respectively， and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat， respectively.[1-2] |
| IC50 | IC50: 5.9 nM (BTK)[1] |
| In Vitro | GDC-0834 suppresses BTK kinase activity with an IC50 value of 5.9±1.1 nM with Hill slope value of ?0.84±0.07 (mean±S.E.)[1]. GDC-0834 is shown to be a potent reversible inhibitor of six known aldehyde oxidase (AO) substrates with IC50 values ranging from 0.86 to 1.87 μM[2]. |
| In Vivo | The treatment of BALB/c mice with GDC-0834 results in dose-dependent inhibition of pBTK-Tyr223. Animals dosed with 150 or 100 mg/kg GDC-0834 for 2 h show complete inhibition of pBTK-Tyr223 levels in blood， with a mean inhibition of 97 and 96%， respectively. In the rat CIA study， GDC-0834 inhibits pBTK-Tyr223 in rat blood in a dose-dependent manner. The IC50 estimate of pBTK-Tyr223 inhibition in rats is determined to be 5.6±1.6 μM with m of 0.51±0.087 (mean±S.E.)[1]. |
| 动物实验 | Mice[1] To investigate the in vivo potency of GDC-0834 on inhibiting pBTK-Tyr223 in blood in mice， BALB/c mice are dosed orally with GDC-0834 at 25， 50， 100， and 150 mg/kg， and the terminal blood samples are collected from mice at 2， 4， or 6 h postdose. Three animals per each time point are sacrificed for the blood sampling. GDC-0834 plasma levels are quantitated using LC/MS/MS as described below. Levels of BTK-pTyr223 (pBTK) and total BTK are determined in blood by Western blot. A rabbit polyclonal pBTK and a mouse monoclonal total BTK are used. The bands are quantified with LI-COR Odyssey imager and software. The pBTK is normalized to total BTK in each sample. Normalized values for each sample are then compared with values from normalized vehicle-treated blood samples to determine the percentage of inhibition of BTK-Tyr223 phosphorylation in the sample. Specifically， the following equation is used: percentage of inhibition of pBTK=(1?(normalized pBTK of test sample/normalized pBTK of vehicle-treated sample))×100. A secondary objective of this study is to investigate any time delays in effect by examining the time course of pBTK inhibition relative to the GDC-0834 blood concentrations. No hysteresis is evident in plots of pBTK inhibition versus GDC-0834 concentration. Rats[1] Arthritis is induced in female Lewis rats at Bolder BioPATH. In brief， animals (10 rats per group) are anesthetized with isoflurane and injected with 300 μL of Freund‘s incomplete adjuvant containing 2 mg/mL bovine type II collagen at the base of the tail and two sites on the back on days 0 and 6. Oral dosing of GDC-0834 [vehicle， 1， 3， 10， 30， and 100 mg/kg b.i.d. (twice daily) at 12-h intervals， vehicle， 10， 30， 100 mg/kg once daily (QD) at 24-h intervals， and 100 mg/kg every other day (Q2D) at 48 intervals] is initiated on day 0 of the study and continued through day 16. The caliper measurements of ankles are taken every day starting from day 9 to day 17， and the area under the ankle diameter-time curves are calculated based on the trapezoidal rule. After final body weight measurement on day 17， animals are anesthetized for terminal serum collection and then euthanized for tissue collection. Ankle diameters are also measured in the normal rats treated with the vehicle (n=6). |
| 激酶实验 | Btk activity is quantified by determining phosphorylation of an exogenous peptide product in a Lanthascreen assay. The Km values for ATP and peptide are also assessed before selecting the final reaction conditions. In a final reaction volume of 25 μL， Btk [human， full-length， C-terminal V5-6× His， expressed in Sf9 cells; 0.075 ng/25 μL reaction) is incubated with 50 mM HEPES， pH 7.5， 10 mM MgCl2， 2 mM MnCl2， 2 mM dithiothreitol， 0.2 mM NaVO4， 0.01% casein， 0.01% Triton X-100， 2.5% glycerol， and 0.4 μM fluorescein poly-Glu/Ala/Tyr]. The reaction is initiated by the addition of ATP to 25 μM (Km of ATP). After incubation for 60 min at room temperature， the reaction is stopped by the addition of a final concentration of 2 nM Tb-PY20 detection antibody in 60 mM EDTA for 30 min at room temperature. Detection is determined on a PerkinElmer Envision with 340 nM excitation and emission at 495 and 520 nm. The response versus BTK inhibitor concentration data are fitted with GraphPad Prism version 5.00[1]. |
| 数据来源文献 | [1]. Liu L， et al. Antiarthritis effect of a novel Bruton‘s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J [2]. Sodhi JK， et al. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 2015 Jun;43(6):908-15 |
| 单位 | 瓶 |
| 表格1 | |*|1mg|5mg|10mg|$$|1mM|1.6758mL|8.3789mL|16.7577mL|$$|5mM|0.3352mL|1.6758mL|3.3515mL|$$|10mM|0.1676mL|0.8379mL|1.6758mL| |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
【思路解读】一篇 10 分 SCI 文章，教你入手「铁死亡」的国自然课题设计思路
对「铁死亡」的抗性是 PI3K-AKT 信号通路激活的结果，研究者通过药理学手段抑制了该通路，发现 PI3K 抑制剂 GDC-0941 和 AKT 抑制剂 MK-2206 均使 BT474 和 MDA-MB-453 细胞（均具有该通路的激活突变）对「铁死亡」敏感，表明 PI3K-AKT-mTOR 通路的持续激活可保护癌细胞免受细胞「铁死亡」。 图片来源：参考文献 5 Figure 1 2. mTORC1，而不是 mTORC2，可以抑制「铁死亡」 mTOR 信号传导可经由 mTORC1/mTORC2
介绍TCGA 是癌症基因组分析中相当流行的数据库，针对里面数据的挖掘结果、软件工具发表了许多 CNS 文章，不过现在已经被整合进 GDC 数据平台了。虽然现在测序技术发展的很快，单个样本测序成本比较之前而言低了很多，但是对于单个课题组研究而言，对大量样本的测序成本还是有些难以承受。TCGA 的数据集提供了一个很好的平台，我们既可以分析它衍生新的课题，也可以通过它为自己分析的结果佐证。今天的分析用的就是 TCGA 肺腺癌的数据集（TCGA-LUAD），可以点击这里进入 UCSC 的数据
- - - - - C687 KGF - - - - - 50ng/ml 50ng/ml - - - CH73 Vitamin C - - - - - - 0.25mM 0.25 mM 0.25 mM 0.25 mM LDN-193189 - - - - - - 0.1μM 0.1 μM 0.1 μM - GDC
技术资料暂无技术资料 索取技术资料
GDC-0834
¥1390 - 4990
